Maryland-based Conformis Inc. (Nasdaq: CFMS) and SITES Medical in Columbia City have entered into a non-exclusive development and supply agreement. The companies say they will work together to incorporate SITES Medical’s OsteoSync Ti Technology into future Conformis’ knee replacement products.
SITES Medical, which develops orthopedic technologies for original equipment manufacturers, says its titanium bone ingrowth material is designed “to meet the needs of health stakeholders from both clinical and economic standpoints.”
“We are excited to be partnering with Conformis, a company that has brought a high degree of innovation to the joint replacement field,” said Greg Stalcup, president of SITES Medical. “We look forward to working with the Conformis team to combine our respective technologies to deliver new generations of high performance, cost effective, and OR-efficient products to the market.”
SITES says testing of its technology proved to be nearly twice as strong as titanium plasma spray or beads, and between 2 and 5 times that of titanium 3D printed materials.